# SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

> **NCT06122389** · PHASE3 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

## Interventions

- **DRUG:** SHR2554; Chidamide analog tablets
- **DRUG:** SHR2554 analog tablets; Chidamide

## Key facts

- **NCT ID:** NCT06122389
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122389, "SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06122389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*